Magnus Corfitzen - Ascelia Pharma Chief Officer

ACE Stock

SEK 2.90 0.11 3.65%

Insider

Magnus Corfitzen is Chief Officer of Ascelia Pharma AB

Age	48
Phone	46 735 179 118
Web	https://www.ascelia.com

Ascelia Pharma Management Efficiency

The company has return on total asset (ROA) of (0.3347) % which means that it has lost $0.3347 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.537) %, meaning that it generated substantial loss on money invested by shareholders. Ascelia Pharma's management efficiency ratios could be used to measure how well Ascelia Pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Ascelia Pharma to Peers

Predict price of Ascelia Pharma

Ascelia Pharma AB has accumulated 553 K in total debt. Ascelia Pharma AB has a current ratio of 23.22, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Ascelia Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Ascelia Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ascelia Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ascelia to invest in growth at high rates of return. When we think about Ascelia Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Annika MBA	Oncopeptides AB	57
	Bent MSc	ExpreS2ion Biotech Holding	N/A
	Karin Nielsen	Saniona AB	N/A
	Sren MSc	Hansa Biopharma AB	58
	MSc MD	Oncopeptides AB	N/A
	MBA MSc	Saniona AB	63
	Kristina Luthman	Oncopeptides AB	N/A
	Mattis Ranthe	ExpreS2ion Biotech Holding	N/A
	Janus Larsen	Saniona AB	51
	Peter Nygren	Oncopeptides AB	64
	Anne Lanner	Hansa Biopharma AB	54
	Jorgen Drejer	Saniona AB	68
	MSc MSc	Oncopeptides AB	53
	Jakob Lic	Oncopeptides AB	51
	Palle MS	Saniona AB	65
	Katja Margell	Hansa Biopharma AB	N/A
	Lars Petersen	ExpreS2ion Biotech Holding	N/A
	Max Sogaard	ExpreS2ion Biotech Holding	N/A
	Rami Levin	Saniona AB	54
	Mette Thorn	ExpreS2ion Biotech Holding	N/A
	Linda Holmstrom	Oncopeptides AB	N/A

Ascelia Pharma AB operates as an oncology focused specialty pharmaceutical company that develops medicines to enhance the life expectancy for people living with cancer and cancer-related diseases in Sweden and Denmark. The company was founded in 2000 and is headquartered in Malm, Sweden. Ascelia Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 4 people. Ascelia Pharma AB (ACE) is traded on Stockholm Exchange in Sweden and employs 21 people.

Management Performance

	Return On Equity	-0.54
	Return On Asset	-0.33

Ascelia Pharma AB Leadership Team

Elected by the shareholders, the Ascelia Pharma's board of directors comprises two types of representatives: Ascelia Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ascelia. The board's role is to monitor Ascelia Pharma's management team and ensure that shareholders' interests are well served. Ascelia Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ascelia Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Carl MD, Chief Officer
	Julie Brogren, Deputy Officer
	Magnus Corfitzen, Chief Officer
	Despina Hedin, Chief Officer
	Mikael Widell, Head Communications
	Andreas Norlin, Chief Officer

Ascelia Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ascelia Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.54
	Return On Asset	-0.33
	Current Valuation	359.6 M
	Shares Outstanding	33.67 M
	Shares Owned By Insiders	22.73 %
	Shares Owned By Institutions	31.16 %
	Price To Book	2.34 X
	EBITDA	(129.45 M)
	Net Income	(125.9 M)
	Cash And Equivalents	219.15 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Ascelia Stock Analysis

When running Ascelia Pharma's price analysis, check to measure Ascelia Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascelia Pharma is operating at the current time. Most of Ascelia Pharma's value examination focuses on studying past and present price action to predict the probability of Ascelia Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascelia Pharma's price. Additionally, you may evaluate how the addition of Ascelia Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC